Yingxin Xu

1.8k total citations · 1 hit paper
56 papers, 1.3k citations indexed

About

Yingxin Xu is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yingxin Xu has authored 56 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Immunology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yingxin Xu's work include Cancer Immunotherapy and Biomarkers (8 papers), Multiple Myeloma Research and Treatments (7 papers) and CAR-T cell therapy research (7 papers). Yingxin Xu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Multiple Myeloma Research and Treatments (7 papers) and CAR-T cell therapy research (7 papers). Yingxin Xu collaborates with scholars based in United States, China and United Kingdom. Yingxin Xu's co-authors include Isabella Sledge, Matthew R. Reynolds, Amber Martin, Peter Spector, Manu Sondhi, Hugh Calkins, Catherine J. Williams, Kyle Fahrbach, Yifan Yang and Qi Shen and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Yingxin Xu

53 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency Ablation

2009 586 citations Hugh Calkins, Peter Spector et al. profile →

Peers

Countries citing papers authored by Yingxin Xu

Since Specialization

Citations

This map shows the geographic impact of Yingxin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingxin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingxin Xu more than expected).

Fields of papers citing papers by Yingxin Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingxin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingxin Xu. The network helps show where Yingxin Xu may publish in the future.

Co-authorship network of co-authors of Yingxin Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Yingxin Xu. A scholar is included among the top collaborators of Yingxin Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingxin Xu. Yingxin Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review 2025 ·European Journal Of Haematology ·Bastian von Tresckow, (unknown), (unknown), (unknown), Yuting Kuang, Jennifer Uyei, Mohsin Shah, (unknown), (unknown), (unknown), (unknown), Christian Hampp, Jessica J. Jalbert, Alexi Archambault, Yingxin Xu, (unknown), Srikanth Ambati, Hesham Mohamed, Qiufei Ma, Ana Jiménez Ubieto	0
2	Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison 2025 ·Dermatology and Therapy ·Sonja Ständer, Andreas Pinter, (unknown), Patricia Guyot, Yingxin Xu, Amy Praestgaard, Nick Freemantle, Ana B. Rossi, (unknown), Zhixiao Wang, (unknown), (unknown)	1
3	A Couple-Based Intervention for Chinese Older Adults With Type 2 Diabetes 2025 ·JAMA Network Open ·(unknown), (unknown), Yingxin Xu, Xiulin Fan, (unknown), Dong Xu, Jing Liao	1
4	Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials 2025 ·Ophthalmology and Therapy ·Scott M. Friedman, Yingxin Xu, (unknown), Andreas Kuznik, (unknown), (unknown), (unknown), Theodore Leng, Nimesh Patel	0
5	Enhancing systematic literature reviews with generative artificial intelligence: development, applications, and performance evaluation 2025 ·Journal of the American Medical Informatics Association ·Ying Li, Surabhi Datta, Majid Rastegar-Mojarad, (unknown), (unknown), (unknown), Conor Liston, (unknown), Xiaoyan Wang, Yingxin Xu	4
6	Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). 2024 ·Journal of Clinical Oncology ·Sundar Jagannath, Hans C. Lee, Joshua Richter, Jeffrey A. Zonder, James E. Hoffman, Zheng‐Yi Zhou, (unknown), Mirko Fillbrunn, (unknown), (unknown), Qiufei Ma, (unknown), Yingxin Xu, (unknown), James Harnett, Tito Roccia, Glenn S. Kroog, Karen Rodriguez-Lorenc, Yariv Houvras, Naresh Bumma	1
7	P-403 Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jeffrey A. Zonder, Hans C. Lee, Joshua Richter, Naresh Bumma, Zheng‐Yi Zhou, (unknown), Mirko Fillbrunn, (unknown), (unknown), (unknown), Qiufei Ma, (unknown), Yingxin Xu, (unknown), James Harnett, Tito Roccia, Glenn S. Kroog, Karen Rodriguez Lorenc, Yariv Houvras, Sundar Jagannath	1
8	Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison 2024 ·The Journal of Allergy and Clinical Immunology In Practice ·Claire Hopkins, Joseph K. Han, Wytske J. Fokkens, Martin Wagenmann, Patricia Guyot, Asif Khan, Scott D. Nash, Zhixiao Wang, Yingxin Xu, Jérôme Msihid, Binod Neupane, (unknown), Claus Bachert	11
9	Elevated gut microbiota metabolite bile acids confer protective effects on clinical prognosis in ischemic stroke patients 2024 ·Frontiers in Neuroscience ·Zhaobin Wang, Jing Li, Yingxin Xu, (unknown), Zhe Zhang, Qin Xu, Jinxi Lin, Yong Jiang, Yongjun Wang, Jing Jing, Anxin Wang, Xia Meng	7
10	Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer 2023 ·Frontiers in Oncology ·Josephine Feliciano, (unknown), Yingxin Xu, Ruben G.W. Quek, Andreas Kuznik, Jean‐François Pouliot, Giuseppe Gullo, Petra Rietschel, Patricia Guyot, (unknown), (unknown), (unknown), (unknown), Nick Freemantle	5
11	Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50% 2022 ·Therapeutic Advances in Medical Oncology ·Nick Freemantle, Yingxin Xu, (unknown), Patricia Guyot, Chieh-I Chen, (unknown), (unknown), (unknown), Andreas Kuznik, Kokuvi Atsou, (unknown), Jean‐François Pouliot, Giuseppe Gullo, Petra Rietschel	1
12	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma 2020 ·Respiratory Medicine ·Eric D. Bateman, Asif Khan, Yingxin Xu, Patricia Guyot, Jingdong Chao, Siddhesh Kamat, Paul Rowe, Heather Burnett, Jérôme Msihid, David M. Weinreich, Ian Pavord	22
13	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis 2018 ·Journal of Cancer Research and Clinical Oncology ·Howard L. Kaufman, Lawrence H. Schwartz, William N. William, Mario Sznol, Kyle Fahrbach, Yingxin Xu, Eric Masson, (unknown)	23
14	A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis 2018 ·Clinical Lymphoma Myeloma & Leukemia ·Meletios Α. Dimopoulos, Jonathan L. Kaufman, Darrell White, Gordon Cook, Maria Teresa Rizzo, Yingxin Xu, Kyle Fahrbach, (unknown), (unknown), (unknown), Annette Lam	18
15	Indirect Treatment Comparisons of Ibrutinib Versus Physician’s Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia 2017 ·Clinical Therapeutics ·Sonja Sorensen, Mark Wildgust, Nishan Sengupta, (unknown), Joris Diels, Suzy Van Sanden, Yingxin Xu, (unknown)	7
16	Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature 2012 ·American Heart Journal ·Jeffrey S. Berger, (unknown), Brian G. Katona, Juan Maya, Gayatri Ranganathan, Yingxin Xu, Mkaya Mwamburi	22
17	Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma 2011 ·Cancer Biology & Therapy ·Pei Zhou, Ping Liang, Baowei Dong, Xiaoling Yu, Zhiyu Han, Yingxin Xu	53
18	Simulator platform of fire control system based on VR technology 2008 ·Jisuanji gongcheng yu sheji ·Yingxin Xu, (unknown)	1
19	Abstract 2759: Treatment of Atrial Fibrillation with Anti-arrhythmic Drugs or Radio Frequency Ablation: Two Systematic Literature Reviews and Meta-analyses 2008 ·Circulation ·Hugh Calkins, Matthew Reynolds, Peter Spector, Manu Sondhi, Yingxin Xu, Amber Martin, Catherine J. Williams, Isabella Sledge	1
20	Study of biodegradable and self-expandable PLLA helical biliary stent in vivo and in vitro 2006 ·Journal of Materials Science Materials in Medicine ·Bo Meng, Jing Wang, Ning Zhu, Qingyuan Meng, Fuzhai Cui, Yingxin Xu	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact